A Phase 3 trial of oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China.
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2016
At a glance
- Drugs MRX I (Primary) ; Linezolid
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- 20 Oct 2016 According to a MicuRx media release, results from this trial are expected in 218.
- 20 Oct 2016 According to a MicuRx media release, status changed from planning to recruiting.
- 07 Oct 2016 New trial record